Coromandel International Q4 Revenue Up 20 Percent PAT Falls 76 Percent to Rs 140 Crore
- May 8, 2026
- Posted by: Neeraj Pandey
- Category: News
Coromandel International Q4 results for FY26 announced on 7 May 2026 showed consolidated revenue from operations rising 20.35% year on year to Rs 6,003.66 crore, but consolidated profit after tax declined sharply by 76% to Rs 140 crore. The Coromandel International Q4 PAT contraction reflects higher phosphatic fertiliser input costs, changes in subsidy receipts, and the impact of inventory valuation on reported margins in the January to March 2026 quarter.
Investors monitoring the Coromandel International Q4 results FY26 should contextualise the PAT decline within the broader fertiliser sector dynamics including phosphoric acid and sulphur cost trends, DAP and NPK realisations, and the timing of government subsidy disbursements. The Coromandel International Q4 revenue growth of 20% confirms strong underlying demand for crop nutrition products heading into the Kharif season.
Get Free Stock Recommendations on Univest
Coromandel International Q4 FY26 Results at a Glance
| Metric | Q4 FY26 / FY26 | Change |
|---|---|---|
| Q4 Revenue | Rs 6,004 crore | +20.35% YoY |
| Q4 Consolidated PAT | Rs 140 crore | -76% YoY |
Track live financials and analyst ratings on the Univest Screener.
Key Highlights from Coromandel International Q4 FY26
Revenue Growth Driven by Strong Fertiliser Volumes
The Coromandel International Q4 revenue growth of 20.35% to Rs 6,003.66 crore reflects robust fertiliser demand across its core South and Central Indian markets. Phosphatic fertiliser volumes grew meaningfully as farmers prepared for the Kharif season, and the company’s crop protection and specialty nutrients segments also contributed to topline growth in the Coromandel International Q4 quarter.
PAT Impacted by Subsidy and Cost Timing
The Coromandel International Q4 PAT declined 76% to Rs 140 crore due to a combination of higher raw material costs including phosphoric acid and sulphur, unfavorable subsidy receipt timing, and inventory valuation impacts. The fertiliser subsidy model in India means that revenue recognition and cash receipts can be misaligned, creating significant quarter-to-quarter PAT volatility in the Coromandel International Q4 numbers.
Crop Protection and Specialties Growth
The Coromandel International Q4 results include contributions from its crop protection business which delivered steady growth on the back of new product launches and expanding distribution reach. The company’s specialty plant nutrition products continued to gain traction with progressive farmers, diversifying the Coromandel International Q4 revenue mix beyond commoditised fertilisers.
Risks to Monitor
- Subsidy policy changes: Any reduction in fertiliser subsidy rates or delayed disbursement by the government would directly compress Coromandel International Q4 margins.
- Raw material cost volatility: Phosphoric acid and sulphur prices are globally traded and volatile, creating margin uncertainty for Coromandel International Q4 production economics.
- Monsoon dependence: A below-normal monsoon would reduce Kharif fertiliser demand, directly impacting Coromandel International Q4 volumes in the following quarter.
- Competition from imports: Government policies on fertiliser imports and pricing can create competitive pressure on domestic manufacturers like Coromandel.
Conclusion
The Coromandel International Q4 results FY26 present a nuanced picture with strong revenue growth of 20.35% to Rs 6,003.66 crore offset by a 76% PAT decline to Rs 140 crore due to unfavorable input cost and subsidy timing dynamics. The Coromandel International Q4 results should be evaluated in the context of these cyclical factors rather than interpreted as a structural earnings decline.
For FY27, the most important variable for Coromandel International Q4 investors is whether phosphoric acid costs moderate and whether subsidy receipts normalise, as these two factors together could drive a significant earnings recovery from the depressed Coromandel International Q4 base.
Download the Univest iOS App or Univest Android App for live Q4 results tracking and expert research.
Disclaimer: This article is for educational and informational purposes only and does not constitute investment advice. Univest analysts are SEBI-registered research analysts (SEBI RA: INH000012449). Investments in the securities market are subject to market risk. Consult a SEBI-registered financial advisor before making any investment decisions.
Frequently Asked Questions
What was the Coromandel International Q4 FY26 PAT?
Coromandel International Q4 FY26 consolidated PAT declined 76% to Rs 140 crore from a higher base in Q4 FY25, due to higher phosphoric acid input costs, subsidy timing impacts, and inventory valuation adjustments.
What is the Coromandel International Q4 FY26 revenue?
Revenue from operations in the Coromandel International Q4 results FY26 stood at Rs 6,003.66 crore, up 20.35% year on year, driven by strong fertiliser demand and crop protection product sales.
Why did Coromandel International Q4 PAT fall despite revenue growth?
The Coromandel International Q4 PAT decline of 76% despite 20% revenue growth is due to higher phosphoric acid and sulphur raw material costs, changes in the timing of government subsidy receipts, and inventory valuation impacts.
What is the Coromandel International business model?
Coromandel International Q4 revenues come primarily from phosphatic fertilisers (DAP and NPK) produced at its plants and sold through an extensive dealer network, along with crop protection chemicals and specialty nutrition products.
What is the Coromandel International Q4 FY27 outlook?
Coromandel International Q4 FY27 earnings recovery depends on phosphoric acid cost moderation, timely government subsidy disbursements, and continued volume growth driven by a normal Kharif season.
Recent Article
Why Is Liberty Shoes Share Price Falling: Key Reasons and Investor Analysis 2026
Why Is Shemaroo Entertainment Share Price Falling: Key Reasons and Investor Analysis 2026
Why Is Orchid Pharma Share Price Falling: Key Reasons and Investor Analysis 2026
Why Is Bajaj Holdings and Investment Share Price Falling: Key Reasons and Investor Analysis 2026
Why Is Prism Johnson Share Price Falling: Key Reasons and Investor Analysis 2026
